Bonraybio Co., Ltd.
Bonraybio Co., Ltd., a development stage company, manufactures medical instruments and solutions for the male infertility market. The company provides LensHooke X12 PRO semen analysis systems; and LensHooke X1 PRO semen quality analyzers. It also offers consumables, such as CS3 semen test slides; CA0/CA1 sperm separation solutions; and CS1 semen test cassettes. In addition, the company provides X… Read more
Bonraybio Co., Ltd. (6955) - Net Assets
Latest net assets as of September 2025: NT$611.35 Million TWD
Based on the latest financial reports, Bonraybio Co., Ltd. (6955) has net assets worth NT$611.35 Million TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$661.63 Million) and total liabilities (NT$50.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$611.35 Million |
| % of Total Assets | 92.4% |
| Annual Growth Rate | 34.08% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 45.64 |
Bonraybio Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Bonraybio Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bonraybio Co., Ltd. (2021–2024)
The table below shows the annual net assets of Bonraybio Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$571.35 Million | +105.18% |
| 2023-12-31 | NT$278.46 Million | +10.15% |
| 2022-12-31 | NT$252.80 Million | +6.67% |
| 2021-12-31 | NT$236.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bonraybio Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 17411300000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$71.01 Million | 12.43% |
| Other Components | NT$500.33 Million | 87.57% |
| Total Equity | NT$571.35 Million | 100.00% |
Bonraybio Co., Ltd. Competitors by Market Cap
The table below lists competitors of Bonraybio Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
SKY Metals Ltd
AU:SKY
|
$55.16 Million |
|
Dicot AB
ST:DICOT
|
$55.17 Million |
|
SPARQ Corp.
OTCQB:SPRQF
|
$55.18 Million |
|
The BORN Korea
KO:475560
|
$55.19 Million |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
$55.15 Million |
|
Surrozen Inc
NASDAQ:SRZN
|
$55.14 Million |
|
Me2on Co. Ltd
KQ:201490
|
$55.14 Million |
|
KPX Chemical
KO:025000
|
$55.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bonraybio Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 278,457,000 to 571,349,000, a change of 292,892,000 (105.2%).
- Net income of 68,365,000 contributed positively to equity growth.
- Dividend payments of 3,417,000 reduced retained earnings.
- New share issuances of 227,693,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$68.36 Million | +11.97% |
| Dividends Paid | NT$3.42 Million | -0.6% |
| Share Issuances | NT$227.69 Million | +39.85% |
| Other Changes | NT$251.00K | +0.04% |
| Total Change | NT$- | 105.18% |
Book Value vs Market Value Analysis
This analysis compares Bonraybio Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.51x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.57x to 7.51x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$10.44 | NT$173.00 | x |
| 2022-12-31 | NT$11.14 | NT$173.00 | x |
| 2023-12-31 | NT$12.27 | NT$173.00 | x |
| 2024-12-31 | NT$23.04 | NT$173.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bonraybio Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.97%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 30.67%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.09x
- Recent ROE (11.97%) is above the historical average (2.12%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -13.38% | -56.34% | 0.21x | 1.11x | NT$-55.41 Million |
| 2022 | 0.67% | 1.59% | 0.38x | 1.11x | NT$-23.59 Million |
| 2023 | 9.24% | 16.11% | 0.50x | 1.14x | NT$-2.12 Million |
| 2024 | 11.97% | 30.67% | 0.36x | 1.09x | NT$11.23 Million |
Industry Comparison
This section compares Bonraybio Co., Ltd.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,274,214,400
- Average return on equity (ROE) among peers: 6.56%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bonraybio Co., Ltd. (6955) | NT$611.35 Million | -13.38% | 0.08x | $55.16 Million |
| Health & Life Co., Ltd. (1781) | $372.58 Million | -4.71% | 1.15x | $12.97 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.65 Million |
| Wellell Inc (4106) | $1.31 Billion | 13.81% | 0.24x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.33 Billion | 1.93% | 1.30x | $38.32 Million |
| United Orthopedic (4129) | $1.77 Billion | 7.55% | 0.46x | $300.33 Million |
| Dynamic Medical Technologies (4138) | $1.76 Billion | 11.67% | 0.71x | $39.41 Million |
| Ok Biotech Co Ltd (4155) | $1.30 Billion | 9.66% | 0.71x | $44.61 Million |
| Bioptik Technology (4161) | $717.83 Million | 6.76% | 1.11x | $30.42 Million |
| EPS Bio Technology Corp. (4183) | $309.15 Million | 10.25% | 0.77x | $4.27 Million |